Capecitabine News and Research

RSS

Report: 83% of cancer doctors face oncology drug shortages

Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510).

4 Jun 2013

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

23 Feb 2013

Oxaliplatin and bevacizumab disappoint for rectal cancer

The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results.

9 Jan 2013

Personalized rectal cancer therapy shows promise

Personalized chemotherapy for rectal cancer results in high rates of pathologic response, indicate the results of a pilot study.

19 Dec 2012

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

10 Dec 2012

Mesupron could extend progression-free survival for metastatic breast cancer patients

Previous research has shown that a family of genes, proteins and enzymes called the uPA system (for urokinase plasminogen activator) plays an active role in different facets of cancer's biology, including tumor cell invasion, the spread of metastases, and the growth of a primary tumor. Mesupron- is a new small molecule inhibitor, taken as a pill, that inhibits the uPA system.

10 Dec 2012

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results from the first large, global Phase III study of Halaven (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

7 Dec 2012

Bevacizumab ruled out for stage III colorectal cancer

Findings from the AVANT trial do not support the use of bevacizumab in patients receiving oxaliplatin-based chemotherapy for resected stage III or high-risk stage II colon carcinoma.

19 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Advanced breast cancer that has spread to the brain could be treated with drug combination

The sizeable and increasing proportion of women with advanced breast cancer whose disease has spread to the brain could be effectively treated systemically with a combination of two drugs, sparing them the debilitating neurological side effects of whole brain radiotherapy (WBRT), suggests new research published Online First in The Lancet Oncology.

2 Nov 2012

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of overall survival (OS) data from the trastuzumab emtansine Phase III trial, EMILIA.

2 Oct 2012

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Roche has reported that updated results from its EMILIA Phase III trial show that patients treated with trastuzumab emtansine had a significant improvement in OS compared to those randomized to standard-of-care therapy.

27 Aug 2012

Study examines whether eribulin offers added benefit to women with breast cancer

Eribulin was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.

17 Aug 2012

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

11 Jul 2012

New Gateway-funded phase II ADAPT study for metastatic colorectal cancer

The Gateway for Cancer Research announces an exciting new Gateway-funded phase II study using ADAPT therapy for treatment of metastatic colorectal cancer based on a 2010 AACR presentation by Dr. Lin and his collaborators.

7 Jul 2012

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

19 Jun 2012

Investigational drug slows metastatic breast cancer progression

Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

11 Jun 2012

T-DM1 better than standard therapy in controlling breast cancer

A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.

5 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer

Aeterna Zentaris Inc. today announced that Johanna Bendell, MD, Director of Gastrointestinal Cancer Research and Associate Director of Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, presented Phase 3 results for perifosine in refractory colorectal cancer yesterday, at the American Society of Clinical Oncology (ASCO) Annual Meeting which is being held in Chicago.

4 Jun 2012

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.